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Objective: The aim of the study was to evaluate serum levels of advanced glycation end 
products (AGEs), receptor for advanced glycation end products (RAGE), and C-reactive 
protein (CRP) in elderly patients with type 2 diabetes mellitus with and without mild 
cognitive impairment (MCI) and to determine the predictors (including AGEs, RAGE, and 
CRP levels) of having MCI in elderly patients with type 2 diabetes.
Methods: Two hundred seventy-six diabetics elders were screened for MCI (using the 
Montreal Cognitive Assessment: MoCA score). Data of biochemical parameters and 
biomarkers were collected.
results: Serum AGEs, RAGE, and CRP levels were significantly increased in MCI 
patients compared to controls. In group of patients with MCI, serum RAGE level was 
positively correlated with AGEs level and with CRP level. RAGE, AGEs, and CRP con-
centrations were positively correlated with HbA1c levels and negatively correlated with 
MoCA score. The univariate logistic regression models revealed that variables, which 
increased the likelihood of diagnosis of MCI in elderly patients with type 2 diabetes were 
higher levels of HbA1c, RAGE, AGEs, CRP, TG, lower level of HDL cholesterol, previous 
CVD, HA, or use of HA drugs, hyperlipidemia, retinopathy, nephropathy, increased num-
ber of co-morbidities, older age, and less years of formal education. HA or use of HA 
drugs, previous CVD, higher level of RAGE and CRP, older age and less years of formal 
education are the factors increasing the likelihood of having MCI in elderly patients with 
type 2 diabetes in multivariable model.
conclusion: In summary, serum AGEs, RAGE, and CRP are increased in the circulation 
of MCI elderly diabetic patients compared to controls. A larger population-based pro-
spective study needs to be performed to further confirm the relationship between AGEs, 
RAGE, and the cognitive decline or progress to dementia.
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inTrODUcTiOn
Diabetes mellitus is one of the important chronic diseases 
worldwide.
The prevalence of type 2 diabetes mellitus (T2DM) raised 
rapidly in the last few decades (Wild et al., 2004). Complications 
include small and large vessels, eyes, kidneys, cranial, and periph-
eral nerves. Recent studies suggested that diabetes is a risk factor 
for cognitive decline and dementia in the elderly (Cukierman 
et al., 2005; Gorska-Ciebiada et al., 2009, 2014). T2DM has a highly 
complicated pathogenesis, so the etiology of cognitive impairment 
in diabetes is probably associated with many factors (Strachan 
et al., 1997). One of the recent hypotheses suggests that low-grade 
chronic inflammation is associated with mild cognitive impairment 
(MCI) or with cognitive decline (Yaffe et al., 2003; Schuitemaker 
et al., 2008). MCI is a transitional stage between normal cognitive 
aging and dementia. One large study has proven that some inflam-
matory parameters, such as C-reactive protein, TNF-α, and IL-6, 
are connected with cognitive dysfunction and decline (Yaffe et al., 
2003). There are evidences from other population-based study 
that there are significant associations between CRP and MCI and 
with the attention and executive function domain score (Roberts 
et al., 2009). Another potential marker of cognitive dysfunction is 
a receptor for advanced glycation end products (RAGE). RAGE is 
a transmembrane receptor that belongs to the immunoglobulin 
super family of cell surface receptors. It interacts with its ligands 
and causes persistent inflammatory responses at vascular wall and 
vascular injuries, a major complication of diabetes (Neeper et al., 
1992; Hori et al., 1996; Schmidt et al., 2000a; Kumano-Kuramochi 
et al., 2009). The major RAGE ligands in diabetes are advanced 
glycation end products (AGEs). They are derivatives of proteins, 
lipids, and ribonucleic acids. Serum AGEs levels increases with 
age and with diabetes or hyperglycemic states (Ulrich and Cerami, 
2001). RAGE-mediated mechanisms play a crucial role in diabetes 
complications because they induce reactive oxygen species-
mediated inflammation in vascular wall (Win et al., 2012). RAGE 
is also an important cell-signaling receptor involved in cognitive 
impairment. Recent studies report the association between RAGE 
levels and cognitive impairment in Alzheimer’s disease (Deane 
and Zlokovic, 2007). Increased expression of RAGE was found 
in neurons and microglia in the hippocampus (Lue et al., 2001). 
Some authors have suggested that RAGE and other receptors 
could be involved in the injury of the brain in Alzheimer’s disease 
and diabetes by microglial activation and oxygen-mediated neu-
roinflammation (Lue et al., 2012).
Data concerning serum AGEs and RAGE levels in MCI sub-
jects with diabetes are lacking; therefore, the aim of the study was 
to (1) evaluate serum levels of AGEs, RAGE, and CRP in elderly 
patients with T2DM with and without MCI and (2) determine 
the predictors (including AGEs, RAGE, and CRP levels) of having 
MCI in elderly patients with T2DM.
MaTerials anD MeThODs
study Population
A survey was conducted among unselected 276 elders who 
attended to outpatient clinic belonged to the Department of 
Internal Medicine and Diabetology, University Hospital no 1 
in Lodz, Poland. A brief screening for recruitment was con-
ducted by the investigators to identify potential participants. 
We included patients aged 65 and over with diabetes type 2 
diagnosed minimum 1  year earlier, subjects who had been 
able to understand and cooperate with study procedures. The 
exclusion criteria were diagnosed depression or dementia, 
use of possible or known cognition-impairing drugs in the 
previous 3-month, presence of neoplasm, constant alcohol or 
substance abuse, severe visual, mobility, or motor coordina-
tion impairment, history of head trauma, inflammatory or 
infectious brain disease, severe neurological or psychiatric 
illness (Table 1).
Written informed consent was obtained from the participants 
at the beginning of the study. The first part of visit included a 
morning blood draw after a 10- to 12-h overnight fast, blood 
pressure measurements, height and weight assessment, and 
complete physical examination. Then, patients had eaten a 
breakfast followed by capillary glucose level measuring to ensure 
that participants were not hypoglycemic at the time of cognitive 
testing. The second part of visit took place in a private area in 
the clinic. Subjects completed a questionnaire describing baseline 
demographics and underwent cognitive testing.
Participant characteristics, clinical 
evaluation, and risk Factor assessment
Demographic variables and possible risk factors were recorded 
in a standardized interview. Weight and height were measured 
to calculate body mass index [BMI = weight/height2 (kg/m2)]. 
The systolic and diastolic blood pressures (millimeter of mer-
cury) were measured with the patient in sitting position after 
5  min of rest. The detailed medical history of diabetes type 2 
was taken and includes diabetes duration, currant treatment 
for diabetes and complications if present, family history of 
diabetes, co-morbid diseases of the patient [hyperlipidemia, 
hypertension, cardiovascular disease (CVD), lung disease, 
cancer, gastrointestinal tract diseases] and their treatment. 
Educational level was recorded in years of education. Smoking 
was classified as current, past, or never. Physical activity was 
recorded if any present. Diabetic vascular complications were 
assessed based on the existence of nephropathy, retinopathy, 
neuropathy, CVD, and stroke. Hypertension was defined as 
TaBle 1 | The inclusion and exclusion criteria of the study.
The inclusion criteria
Age ≥65 years
Diabetes type 2 diagnosed minimum 1 year earlier
Full ability to understand and cooperate with study procedures
The exclusion criteria
Diagnosed depression or dementia
Use of possible or known cognition-impairing drugs in the previous 3-month
Presence of neoplasm
Constant alcohol or substance abuse
Severe visual, mobility, or motor coordination impairment
History of head trauma
Inflammatory or infectious brain disease
Severe neurological or psychiatric illness
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either a history of hypertension or use of any antihypertensive 
agents, Hyperlipidemia defined as use of any lipid lowering 
agent or an untreated serum LDL cholesterol level 2.6 mmol/l 
or/and triglycerides 1.7 mmol/l.
Blood Biochemistry
After overnight fasting, blood samples were taken by venipunc-
ture to assess serum levels of glycosylated hemoglobin (HbA1c), 
total cholesterol, triglycerides, low-density lipoprotein cholesterol 
(LDL-C), and high-density lipoprotein cholesterol (HDL-C). All 
the parameters were measured in a centralized laboratory.
Determination of serum ages,  
rage, and crP
The serum levels of AGEs, RAGE were assessed using ELISA kit 
(EIAab, Wuhan, China), and CRP was determined by Quantikine 
Human Immunoassay ELISA kit (R&D System, Minneapolis, 
MN, USA) according to the instructions of the manufacturer. 
Minimum detectable concentrations were 0.78 ng/ml for AGEs 
and 4.12 pg/ml for RAGE, 1 × 10−5 mg/l for CRP.
neuropsychological evaluations
All participants underwent the following tests: the Montreal 
Cognitive Assessment (MoCA) (Nasreddine et  al., 2005) to 
evaluate the cognitive impairment, long version of the geriat-
ric depression scale (GDS-30) (Yesavage et al., 1982–1983) to 
assessed the depressive mood, Katz Basic Activities of Daily 
living (BADL) and Lawton instrumental activities of daily 
living (IADL) questionnaires to collect information on daily 
activities (Lawton and Brody, 1969; Katz et  al., 1970). The 
MoCA tests 8 cognitive domains, visual–spatial ability, atten-
tion, executive function, immediate memory, delayed memory, 
language, abstraction, calculation, and orientation, for a maxi-
mum total score of 30. The normal MoCA score is ≥26, with 
one point added if the subject has fewer than 12 years of formal 
education. The MoCA is better than other tools to detect MCI 
in the elderly patients with type 2 diabetes (Alagiakrishnan 
et al., 2013). MCI was diagnosed based on criteria established 
by the 2006 European Alzheimer’s Disease Consortium, which 
are currently available standard test (Petersen, 2004; Portet 
et al., 2006). These criteria included absence of dementia. The 
cut-off points for MoCA scores (19/30) are recommended for 
the diagnosis of “dementia” in epidemiological studies. Patients 
with score 19 and below were excluded from the study as 
dementia and sent to psychiatrist for further care. The criteria 
mentioned above included also absence of major repercussions 
on daily life (in our study, measured by Katz BADL and Lawton 
IADL).
This interview was followed by GDS for mood assessment 
(Yesavage et  al., 1982–1983). GDS consists of 30 items. Scores 
ranging from 0 to 9 were considered as normal, and 10 to 19 were 
considered to have depressive symptoms. Score 20 and above was 
excluded from the study as severe depressive symptomatology 
and sent to psychiatrist for further diagnosis.
According to criteria mentioned above 276 older subjects with 
diabetes type 2 were selected into groups: patients with MCI and 
controls (patients without MCI).
ethics
The study was operated in accordance with the World Medical 
Association’s Declaration of Helsinki. Each participant was 
assigned a number by which he/she was identified to keep his 
or her privacy. The approval was obtained from the independ-
ent local ethics committee of Medical University of Lodz No 
RNN/420/13/KB. The purpose, nature, and potential risks of 
the experiments were fully explained to the subjects, and all 
subjects gave written informed consent at the beginning of the 
study. The subjects had the full capacity to consent because they 
maintained general cognitive function and daily activities. We 
included only patients who had been fully able to understand 
and cooperate with study procedures. We excluded subjects 
with diagnosed depression or dementia. There was not any 
surrogate consent procedure (e.g., whereby next of kin or 
legally authorized representative) consented on the behalf of 
participants.
statistical analysis
All data are presented as means ± SD. Normality of distribu-
tions was assessed using the Shapiro–Wilk tests. The descrip-
tive statistics the continuous variables using the Student’s 
t-test or the Mann–Whitney U test whenever applicable and 
non-continuous variables using χ2 test. Pearson correlation 
analysis for normally distributed variables and Spearman rank 
correlation for non-normally distributed variables were used to 
assess relationships. Simple logistic regression model was done 
in order to select the so-called independent factors that increase 
the selection risk of MCI in elderly patients with type 2 diabetes. 
Then, multivariable regression model was done in order to 
select the “strongest” factor from independent risk factors. To 
“optimize” the multivariable model, a stepwise approach was 
used (backward elimination with Wald criteria). Odds ratios 
(OR) were computed and presented with the 95% interval of 
confidence (CI). A p-value of <0.05 was considered statistically 
significant. Statistica 10.0 (StatSoft, Poland, Krakow) was used 
for analysis.
resUlTs
general Description of Mci subjects  
and controls
Table 2 describes the baseline characteristics of the study group. 
Compared with controls patients with MCI were significantly 
older, less educated, had a longer duration of diabetes, more 
were diagnosed with CVD, hypertension, hyperlipidemia, retin-
opathy, nephropathy, and other co-morbidities. MoCA score was 
significantly lower in subjects with cognitive impairment. The 
mean level of HbA1c and triglycerides was significantly higher, 
and level of HDL was lower in patients with MCI compared to 
controls. Furthermore, CRP was found to be increased in MCI 
patients compared to control group (p < 0.001). Lastly, there were 
no significant differences between the groups in sex, BMI, history 
of smoking, stroke, presence of neuropathy, depressive syndrome, 
type of the treatment, systolic and diastolic blood pressure, the 
plasma levels of fasting glucose, and total and LDL cholesterol 
(p > 0.05).
TaBle 2 | Demographic and clinical characteristics of type 2 diabetic elderly patients.
all subjects Mci controls χ2/Z p-value
Number of patients 276 87 189
Age (years)* 73.6 ± 4.8 75.7 ± 4.6 72.6 ± 4.6 −4.96 <0.001
Gender (female/male) 149/127 53/34 96/93 2.46 0.12
Education-years* 11.3 ± 2.4 9.7 ± 1.8 12.0 ± 2.2 7.97 <0.001
Smoked tobacco regularly 93 (33.7%) 26 (29.8%) 67 (35.4%) 0.83 0.36
Duration of T2DM (years)* 8.69 ± 6.23 11.25 ± 6.3 7.51 ± 5.85 −5.96 <0.001
Microvascular complications Retinopathy (%)* 121 (43.8%) 61 (70.1%) 60 (31.7%) 35.6 <0.001
Nephropathy (%)* 97 (35.1%) 43 (49.4%) 54 (28.5%) 11.37 0.007
Neuropathy (%) 56 (20.2%) 20 (22.9%) 36 (19.04%) 0.57 0.45
Macrovascular complications Previous CVD (%)* 109 (39.5%) 71 (81.6%) 38 (20.1%) 94.3 <0.001
Stroke (%) 14 (5.07%) 7 (8.04%) 7 (3.7%) 2.33 0.13
Previous HA/use of HA drugs (%)* 213 (77.2%) 80 (91.95%) 138 (73.01%) 18.3 <0.001
Hyperlipidemia (%)* 218 (78.9%) 81 (93.1%) 132 (69.8%) 12.87 <0.001
Co-morbidity (n)* 4.66 ± 3.11 7.07 ± 3.22 3.55 ± 2.33 −8.15 <0.001
Depressive syndrome (%) 82 (29.7%) 25 (28.7%) 57 (30.2%) 0.06 0.81
Treatment Insulin (%) 130 (47.1%) 42 (48.2%) 88 (46.5%) 0.07 0.79
OAD (%) 222 (80.4%) 71 (81.6%) 151 (79.8%) 0.11 0.74
MoCA score* 25.6 ± 3.07 21.6 ± 1.5 27.4 ± 1.3 13.34 <0.001
BMI (kg/m2) 29.9 ± 3.67 30.4 ± 3.59 29.6 ± 3.68 −1.92 0.054
Systolic blood pressure (mmHg) 136.2 ± 15.9 136.5 ± 16.4 136.05 ± 15.8 −0.25 0.79
Diastolic blood pressure (mmHg) 75 ± 7.9 75.1 ± 8.0 74.9 ± 7.8 −0.09 0.92
Fasting plasma glucose (mmol/l) 129.3 ± 26.1 129.8 ± 27.2 129.1 ± 25.6 −0.14 0.88
HbA1c (%)* 7.24 ± 0.68 7.73 ± 0.71 7.01 ± 0.54 −7.5 <0.001
Serum cholesterol (mmol/l) 10.3 ± 2.18 10.31 ± 2.2 10.29 ± 1.71 −0.5 0.61
Serum LDL-C (mmol/l) 6.06 ± 1.67 6.01 ± 1.64 6.08 ± 1.73 −0.2 0.86
Serum triglycerides (mmol/l)* 9.65 ± 2.23 10.59 ± 2.68 9.22 ± 1.84 −6.6 <0.001
Serum HDL-C (mmol/l)* 2.5 ± 0.51 2.3 ± 0.6 2.67 ± 0.42 6.34 <0.001
CRP (mg/L)* 5.08 ± 2.8 7.6 ± 2.7 3.9 ± 2.0 −9.79 <0.001
AGEs (ng/ml)* 1.4 ± 1.06 2.19 ± 1.12 1.04 ± 0.82 −8.1 <0.001
RAGE (ng/ml)* 2.67 ± 1.68 4.24 ± 1.89 1.94 ± 0.91 −9.7 <0.001
*Significance, p < 0.05; comparing patients with MCI and those without MCI (controls).
T2DM, diabetes type 2; OAD, oral anti-diabetic drug; CVD, cardiovascular disease; HA, hypertension; BMI, body mass index; CHOL, total cholesterol; CRP, C-reactive protein; 
AGEs, advanced glycation end products; RAGE, receptor for advanced glycation end products; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; MoCA, Montreal Cognitive Assessment,
Data are mean − SD values. Mann–Whitney U test (Z), or χ2 test was used to test for significant differences.
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serum rage, ages, and crP  
in Mci and controls
Serum RAGE and AGEs levels were significantly increased in 
MCI patients compared to controls (p < 0.001). As expected, in 
group of diabetic elderly patients with MCI serum RAGE level 
was positively correlated with AGEs level (r = 0.85, p < 0.001) 
and with CRP level (r  =  0.54, p  <  0.001) (Figures  1A–C). 
Furthermore, RAGE, AGEs, and CRP concentrations were 
highly correlated with HbA1c levels (Figures 2A–C). We found 
also positive but weak correlation between these parameters and 
triglycerides levels and negative correlation with HDL levels. 
The results indicated that MoCA score was negatively correlated 
with RAGE, AGEs, and CRP levels (Figures  3A–C). Data are 
presented in Table 3.
logistic regression Models
Because many factors can influence the results we constructed 
the univariate logistic regression models and finally multivariable 
regression model to determine the predictors of having MCI in 
elderly patients with type 2 diabetes. The independent variables 
entered in the model at step one were demographic variables 
(age, gender, education), duration of diabetes, glycemic control 
(HbA1c level), CVDs (MI, angina, stroke), cardiovascular risk 
factors (BMI, smoking status, hyperlipidemia, previous HA or 
use of HA drugs), microvascular complications, presence of 
depressive syndrome, number of co-morbid conditions, levels 
of total, LDL, HDL cholesterol, triglycerides, AGEs, RAGE, and 
CRP. The univariate logistic regression models revealed that vari-
ables which increased the likelihood of having been diagnosed 
with MCI in elderly patients with type 2 diabetes were higher 
levels of HbA1c, RAGE, AGEs, CRP, TG, lower level of HDL cho-
lesterol, previous CVD, HA or use of HA drugs, hyperlipidemia, 
retinopathy, nephropathy, increased number of co-morbidities, 
older age, and less years of formal education (Table 4).
Table 5 shows the results of modeling the risk of having MCI by 
multivariable regression. All variables presented in Table 3 were 
introduced to this model. The multivariable model was optimized 
by the stepwise approach. HA or use of HA drugs, previous CVD, 
higher level of RAGE and CRP, older age and less years of formal 
education are the factors increasing the likelihood of having MCI 
in elderly patients with type 2 diabetes.
FigUre 2 | (a) Correlation of HbA1c with RAGE in group of diabetic elderly patients with MCI. (B) Correlation of HbA1c with AGEs in group of diabetic elderly 
patients with MCI. (c) Correlation of HbA1c with CRP in group of diabetic elderly patients with MCI.
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FigUre 1 | (a) Correlation of RAGE with AGEs in group of diabetic elderly patients with MCI. (B) Correlation of RAGE with CRP in group of diabetic elderly patients 
with MCI. (c) Correlation of AGEs with CRP in group of diabetic elderly patients with MCI.
FigUre 3 | (a) Correlation of MoCA score with RAGE in group of diabetic elderly patients with MCI. (B) Correlation of MoCA score with AGEs in group of diabetic 
elderly patients with MCI. (c) Correlation of MoCA score with CRP in group of diabetic elderly patients with MCI.
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DiscUssiOn
Our results show that patients with MCI had significantly higher 
CRP levels than controls. The increased CRP level is a predictor 
of cognitive impairment in elderly patients with type 2 diabetes. 
This result is consistent with recent reports. CRP – an acute-phase 
protein – is commonly used marker, which participates in low-
grade inflammation in diabetes. It is mainly associated with the 
risk of DM complications. Other researchers had found serum 
levels of CRP were associated with cognition impairment and 
TaBle 3 | relationship of serum levels of ages, rage, and crP with other clinical indicators in group of diabetic elderly patients with Mci.
ages p rage p crP p
r r r
MoCA score −0.5 p < 0.001 −0.61 p < 0.001 −0.37 p < 0.001
HbA1c (%) 0.71 p < 0.001 0.78 p < 0.001 0.63 p < 0.001
Serum cholesterol (mmol/l) 0.1 0.33 0.12 0.25 0.35 0.001
Serum LDL-C (mmol/l) 0.06 0.6 0.08 0.43 0.27 0.01
Serum triglycerides (mmol/l) 0.26 0.014 0.37 p < 0.001 0.28 0.007
Serum HDL-C (mmol/l) −0.2 0.056 −0.33 0.002 −0.19 0.06
AGEs (ng/ml) 1 0.85 p < 0.001 0.51 p < 0.001
RAGE (ng/ml) 1 0.54 p < 0.001
CRP (mg/l) 1
*Significance, p < 0.05; r, correlation coefficient.
BMI, body mass index; CHOL, total cholesterol; CRP, C-reactive protein; AGEs, advanced glycation end products; RAGE, receptor for advanced glycation end products; HbA1c, 
glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MoCA, Montreal Cognitive Assessment.
inversely correlated with MMSE and MoCA scores (Ge et  al., 
2013). In other studies, low-grade inflammation as reflected by 
serum CRP concentrations was found in subjects with cognitive 
dysfunction without dementia and in patients with non-amnestic 
MCI (Haan et al., 2008; Roberts et al., 2009). CRP is also associ-
ated with increased risk of CVD (Ridker et al., 1998). In our study, 
CRP as well as CVD is independent predictors of MCI in diabetic 
patients. Thus, the mechanism of the involvement of low-grade 
inflammation in cognitive impairment is not explained entirely 
by the presence of CVD in diabetic patients. CRP could initiate 
TaBle 4 | assessment results of the risk of having Mci in a simple 
logistic regression model in elderly patients with type 2 diabetes.
Variables analyzed β se of β p-value Or 95% ci
Age (years)* 0.137 0.03 p < 0.001 1.15 1.08–1.22
Gender: female 0.2 0.1 0.12 1.2 0.49–1.59
Education (years)* −0.639 0.09 p < 0.001 0.53 0.44–0.63
Smoked tobacco regularly 0.12 0.1 0.36 0.8 0.6–1.16
Duration of T2DM (years)* 0.097 0.02 p < 0.001 1.1 1.05–1.15
Previous stroke 0.41 0.27 0.14 1.5 0.87–2.58
Previous CVD* 1.43 0.16 p < 0.001 4.19 3.03–5.81
Previous HA or use  
of HA drugs*
0.88 0.22 p < 0.001 2.41 1.55–3.76
Hyperlipidemia* 0.72 0.21 0.001 2.01 1.35–3.12
Retinopathy* 0.8 0.14 p < 0.001 2.24 1.7–2.96
Nephropathy* 0.44 0.13 0.001 1.56 1.2–2.03
Neuropathy 0.11 0.01 0.45 1.12 0.82–1.53
Co-morbidity (n)* 0.426 0.05 p < 0.001 1.53 1.37–1.71
Depressive syndrome 0.03 0.01 0.8 0.96 0.73–1.27
BMI (kg/m2) 0.058 0.03 0.1 1.06 0.98–1.13
HbA1c (%)* 1.69 0.23 p < 0.001 5.47 3.45–8.67
Serum cholesterol (mmol/l) 0.01 0.003 0.95 1.01 0.99–1.01
Serum LDL-C (mmol/l) 0.01 0.004 0.74 1.01 0.99–1.01
Serum triglycerides 
(mmol/l)*
0.02 0.004 p < 0.001 1.02 1.01–1.02
Serum HDL-C (mmol/l)* −0.09 0.018 p < 0.001 0.91 0.87–0.94
CRP (mg/L)* 0.64 0.08 p < 0.001 1.9 1.62–2.22
AGEs (ng/ml)* 1.15 0.16 p < 0.001 3.17 2.31–4.34
RAGE (ng/ml)* 1.19 0.16 p < 0.001 3.28 2.42–4.45
*Significance, p < 0.05.
β, regression coefficient; CI, confidence interval for odds ratio; OR, odds ratio; 
SE, standard error; T2DM, diabetes type 2; CVD, cardiovascular disease; HA, 
hypertension; BMI, body mass index; CHOL, total cholesterol; CRP, C-reactive protein; 
AGEs, advanced glycation end products; RAGE, receptor for advanced glycation 
end products; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol.
TaBle 5 | assessment results of the risk of having Mci in a multivariable 
logistic regression model in elderly patients with type 2 diabetes.
Variables analyzed β se of β p-value Or 95% ci
Age (years)* 0.11 0.05 0.039 1.11 1.0–1.23
Education (years)* −0.45 0.12 p < 0.001 0.64 0.5–0.82
Previous CVD* 1.2 0.24 p < 0.001 3.34 2.06–5.41
Previous HA or use  
of HA drugs*
1.24 0.41 0.002 3.48 1.56–7.76
CRP (mg/l)* 0.44 0.13 0.001 1.55 1.21–1.99
RAGE (ng/ml)* 0.67 0.23 0.004 1.95 1.24–3.06
*Significance, p < 0.05.
β, regression coefficient; CI, confidence interval for odds ratio; OR, odds ratio;  
SE, standard error; CVD, cardiovascular disease; HA, hypertension; CRP, C-reactive 
protein; RAGE, receptor for advanced glycation end products.
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immune cascade reactions leading to neurodegeneration via 
activating the complement system (Eagan et al., 2012).
Like CRP, AGEs–RAGE system stimulated by hyperglycemia 
could be responsible for the deterioration of cognition through 
an immune inflammatory pathway. AGEs – the products of non-
enzymatic glycation on lysine and arginine residues accumulate 
in diabetic tissues – plays the important role in pathogenesis of 
diabetic complications. AGEs binds their receptor – RAGE and 
modulates cellular properties. Stimulation of RAGE results in 
activation of NADPH oxidase and generation of oxidation stress. 
Reactive oxygen species activate also formation of AGEs. In that 
way, the vicious circle is created – hyperglycemia induce AGEs 
generation, then after binding to RAGE increase oxidation stress 
and further production of AGEs (Kislinger et al., 1999; Wautier 
et  al., 2001). Expression of RAGE is increased in CVD and in 
diabetes.
The frequency of cardiac events is higher and the progression 
of atherosclerosis is bigger in patients with diabetes compared to 
age-matched healthy controls. A lot of studies showed elevation 
of RAGE in diabetes and its association with diabetic complica-
tions and severity of the disease (Matsunaga-Irie et al., 2004; Yan 
et al., 2009). There are also data about increasing levels of AGEs 
with age and it is further enhancement by hyperglycemic state 
(Ulrich and Cerami, 2001). The interaction between AGEs and 
RAGE could result in higher inflammation in vascular wall via 
stimulation of oxidative stress. Activation of endothelial, smooth 
muscle cells and mononuclear phagocytes is highly associated 
with diabetic complications, such as nephropathy, retinopathy, 
and atherosclerosis (Schmidt et al., 2000b; Win et al., 2012).
Stimulation of RAGE play crucial role in the pathogenesis 
of T2DM and its complications, but RAGE is also an important 
cell-signaling receptor involved cognitive impairment. RAGE 
expression was found in different structures of the brain, in 
microglia, and astrocytes. In Alzheimer disease, RAGE expres-
sion was increased in inferior frontal cortex and hippocampus. 
The stimulation of RAGE in neurons can lead to increased 
inflammation through activation of the transcription faction 
NF-κB. In diabetes neuroinflammation, vascular injury and also 
activation of microglia could be driven by RAGE and the cascade 
of chemokines and cytokines (Lue et al., 2012).
In our study, AGEs and RAGE levels were significantly 
elevated in MCI subjects. The results are consistent with one 
study, which reported also higher level of AGEs in MCI subject 
with T2DM (Chen et al., 2011). The authors proposed possible 
the mechanism by which AGEs induce MCI in patients with 
type 2 diabetes. It is possible that AGEs stimulate endothelial 
dysfunction and followed the increased permeability of blood 
vessels. Thus, AGEs can accumulates in vascular wall and cause 
its injury. Other explanation could be higher inflammation 
and neural damage via inducing oxidative stress mediated by 
AGEs–RAGE interactions. AGEs could also activate microglia 
and destroy microtubular structure resulting in dysfunction of 
neurons (Chen et al., 2011).
In opposite to this result recent study was evaluated whether 
plasma levels of RAGE are altered in MCI and Alzheimer’s dis-
ease. The authors did not found higher levels of RAGE in MCI 
but the study was performed among only 24 patients without 
vascular disease (only 16% of them had diabetes) (Marksteiner 
et al., 2014).
Expectedly, we found significant relationships between AGEs, 
RAGE, CRP, and glycosylated hemoglobin. Subjects with MCI 
had also more micro complications. Sustained hyperglycemia 
and development of diabetes complications can induce chronic 
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low-grade inflammation and cell activation via AGEs–RAGE 
interaction. In agreement with our results, other studies reported 
that persistent hyperglycemia, indicated by elevated HbA1c, is an 
independent risk factor for the cognitive dysfunction (Ryan and 
Geckle, 2000).
In our previous work, we found that the presence of depres-
sive syndrome is associated with higher levels of inflammatory 
markers in elderly patients with diabetes (Gorska-Ciebiada et al., 
2015). Therefore, we put this parameter into logistic regression 
models; however, we revealed that the presence of depressive 
syndrome have no influence on the results.
limitations
This study provides important insights into AGEs–RAGE system 
disturbances and low-grade inflammation pathologies underly-
ing cognitive impairment in older diabetic patients; however, it is 
not without limitations. First, because our study population was 
relatively small, our results should be interpreted with caution. 
Second, the study was not designed as longitudinal prospective 
investigation. There have been few studies in which the cogni-
tive declines in elderly diabetics were prospectively observed. 
However, the precise mechanisms underlying T2DM-related 
cognitive dysfunction or the development of dementia have not 
yet been elucidated. Furthermore, this investigation was limited 
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